ITRAQ-based proteomic analysis of combination therapy with taurine, epigallocatechin gallate, and genistein on carbon tetrachloride-induced liver fibrosis in rats

Toxicology Letters

Volumn 232, Issue 1, 2015, Pages 233-245

  Cao, Wen ^a   Zhou, Yan ^a   Li, Yan ^b   Zhang, Xuerong ^a   He, Min ^a   Zang, Ning ^a   Zhou, Yi ^a   Liao, Ming ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI UNIVERSITY   (China)

Author keywords

Epigallocatechin gallate; Genistein; ITRAQ; Liver fibrosis; Proteomic; Taurine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOCHEMICAL MARKER; BLOOD CLOTTING FACTOR 7; CARBON TETRACHLORIDE; COLLAGEN TYPE 1; EPIGALLOCATECHIN GALLATE; FIBRINOGEN; GENISTEIN; GLUTATHIONE PEROXIDASE; SUPEROXIDE DISMUTASE; TAURINE; THIOREDOXIN; TRANSFORMING GROWTH FACTOR BETA1; TRIOSEPHOSPHATE ISOMERASE; ANTIOXIDANT; CATECHIN; PROTEIN SERINE THREONINE KINASE; TXN1 PROTEIN, RAT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; BLOOD CHEMISTRY; BLOOD CLOTTING; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; CONTROLLED STUDY; DRUG MECHANISM; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOLYSIS; HISTOPATHOLOGY; ISOBARIC TAGS FOR RELATIVE AND ABSOLUTE QUANTITATION; LIQUID CHROMATOGRAPHY; LIVER FUNCTION; LIVER HISTOLOGY; LIVER PROTECTION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; RAT; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGY; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG EFFECTS; ION EXCHANGE CHROMATOGRAPHY; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER FUNCTION TEST; MALE; METABOLISM; PATHOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

RATTUS;

ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; CATECHIN; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHROMATOGRAPHY, ION EXCHANGE; CHROMATOGRAPHY, LIQUID; COMPUTATIONAL BIOLOGY; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VII; FIBRINOGEN; GENISTEIN; GLYCOLYSIS; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER FUNCTION TESTS; MALE; PROTEIN INTERACTION MAPS; PROTEIN-SERINE-THREONINE KINASES; PROTEOMICS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TAURINE; THIOREDOXINS; TRIOSE-PHOSPHATE ISOMERASE;

EID: 84911414369     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.11.009     Document Type: Article

References (43)

1. Bonis P.A., Friedman S.L., Kaplan M.M. Is liver fibrosis reversible?. New Engl. J. Med. 2001, 344:452-454.
2. Geramizadeh B., Janfeshan K., Saberfiroozi M. Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis B. Saudi J. Gastroenterol. 2008, 14:174-179.
3. Distler J.H., Distler O. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann. Rheum. Dis. 2010, 69:i48-i51.
4. Sánchez-Valle V., Chávez-Tapia N.C., Uribe M., Méndez-Sánchez N. Role of oxidative stress and molecular changes in liver fibrosis: a review. Curr. Med. Chem. 2012, 19:4850-4860.
5. Campo G.M., Avenoso A., Campo S., D'Ascola A., Ferlazzo A.M., Calatroni A. The antioxidant and antifibrogenic effects of the glycosaminoglycans hyaluronic acid and chondroitin-4-sulphate in a subchronic rat model of carbon tetrachloride-induced liver fibrogenesis. Chem. Biol. Interact. 2004, 148:125-138.
6. Gebhardt R. Oxidative stress, plant-derived antioxidants and liver fibrosis. Planta Med. 2002, 68:289-296.
7. Carragher N.O., Unciti-Broceta A., Cameron D.A. Advancing cancer drug discovery towards more agile development of targeted combination therapies. Future Med. Chem. 2012, 4:87-105.
8. Kumar M., Sarin S.K. Systematic review: combination therapies for treatment-naïve chronic hepatitis B. Aliment. Pharmacol. Ther. 2008, 27:1187-1209.
9. Chen Y.X., Zhang X.R., Xie W.F., Li S. Effects of taurine on proliferation and apoptosis of hepatic stellate cells in vitro. Hepatobiliary Pancreat. Dis. Int. 2004, 3:106-109.
10. Kato J., Ido A., Hasuike S., Uto H., Hori T., Hayashi K., et al. Transforming growth factor-β-induced stimulation of formation of collagen fiber network and anti fibrotic effect of taurine in an in vitro model of hepatic fibrosis. Hepatol. Res. 2004, 30:34-41.
11. Miyazaki T., Karube M., Matsuzaki Y., Ikegami T., Doy M., Tanaka N., et al. Taurine inhibits oxidative damage and prevents fibrosis in carbon tetrachloride-induced hepatic fibrosis. J. Hepatol. 2005, 43:117-125.
12. Nakamuta M., Higashi N., Kohjima M., Fukushima M., Ohta S., Kotoh K., et al. Epigallocatechin-3-gallate, a polyphenol component of green tea, suppresses both collagen production and collagenase activity in hepatic stellate cells. Int. J. Mol. Med. 2005, 27:677-681.
13. McCarty M.F., Barroso-Aranda J., Contreras F. Genistein and phycocyanobilin may prevent hepatic fibrosis by suppressing proliferation and activation of hepatic stellate cells. Med. Hypotheses 2009, 72:330-332.
14. Li Y., Luo Y., Zhang X.R., Lin X., He M., Liao M. Combined taurine, epigallocatechin gallate and genistein therapy reduces HSC-T6 cell proliferation and modulates the expression of fibrogenic factors. Int. J. Mol. Sci. 2013, 14:20543-20554.
15. Zhuo L., Liao M., Zheng Li He M., Huang Q., Wei L., et al. Combination therapy with taurine, epigallocatechin gallate and genistein for protection against hepatic fibrosis induced by alcohol in rat. Biol. Pharm. Bull. 2012, 35:1802-1810.
16. Lee T.Y., Chang H.H., Kuo J.J., Shen J.J. Changes of hepatic proteome in bile duct ligated rats with hepatic fibrosis following treatment with Yin-Chen-Hao-Tang. Int. J. Mol. Med. 2009, 23:477-484.
17. Wang H.L., Wu G., Park H.J., Jiang P.P., Sit W.H., van Griensven L.J., et al. Protective effect of Phellinus linteus polysaccharide extracts against thioacetamide-induced liver fibrosis in rats: a proteomics analysis. Chin. Med. 2012, 7:23-28.
18. Niu D., Sui J., Zhang J., Feng H., Chen W.N. iTRAQ-coupled 2-D LC-MS/MS analysis of protein profile associated with HBV-modulated DNA methylation. Proteomics 2009, 9:3856-3868.
19. Yang L., Rudser K.D., Higgins L., Rosen H.R., Zaman A., Corless C.L., et al. Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics. Digest. Dis. Sci. 2011, 56:3305-3315.
20. Zhang L., Jia X., Feng Y., Peng X., Zhang Z., Zhou W., et al. Plasma membrane proteome analysis of the early effect of alcohol on liver: implications for alcoholic liver disease. Acta Biochim. Biophys. Sinica 2011, 43:19-29.
21. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
22. Charlotte W., Lars E. Coomassie staining as loading control in western blot analysis. J. Proteome Res. 2011, 10:1416-1419.
23. Hamano K., Seo Y., Kato H., Kato M., Yano Y., Ninomiya T., et al. Expression of thioredoxin and thioredoxin-binding protein-2 in the liver of patients with chronic hepatitis C as a predictor of response to interferon therapy. Int. J. Mol. Med. 2006, 17:989-995.
24. Mota S., Mendes M., Freitas N., Penque D., Coelho A.V., Cunha C. Proteome analysis of a human liver carcinoma cell line stably expressing hepatitis delta virus ribonucleoproteins. J. Proteomics 2009, 72:616-627.
25. Xie F.J., Zhang Z.P., Lin P., Wang S.H., Zou Z.H., Wang Y.L. Identification of immune responsible fibrinogen beta chain in the liver of large yellow croaker using a modified annealing control primer system. Fish Shellfish Immunol. 2009, 27:202-209.
26. Manzano M.L., Arocena C., Tomás J.F., Hedner U., et al. Measurement of the procoagulant activity of factor VII in patients with liver cirrhosis and normal prothrombin activity: evaluation of the bleeding risk. Blood Coagul. Fibrin. 2000, Suppl 1:S95-S99.
27. Grattagliano I., Palmieri V.O., Portincasa P., Minerva F., Palasciano G. Long-term ursodeoxycholate improves circulating redox changes in primary biliary cirrhotic patients. Clin. Biochem. 2011, 44:1400-1404.
28. Wynn T.A., Ramalingam T.R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 2012, 18:1028-1040.
29. Nishikawa T., Bellance N., Damm A., Bing H., Zhu Z., Handa K., et al. A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease. J. Hepatol. 2014, 60:1203-1211.
30. Orosz F., Oláh J., Ovádl J. Triosephosphate isomerase deficiency: facts and doubts. IUBMB Life 2006, 58:703-715.
31. Hsieh S.Y., Shih T.C., Yeh C.Y., Lin C.J., Chou Y.Y., Lee Y.S. Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics 2006, 6:5322-5331.
32. Poulsen N.A., Andersen V., Møller J.C., Møller H.S., Jessen F., Purup S., et al. Comparative analysis of inflamed and non-inflamed colon biopsies reveals strong proteomic inflammation profilein patients with ulcerative colitis. BMC Gastroenterol. 2012, 12:76-87.
33. Wang J., Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol. Ther. 2008, 7:1875-1884.
34. Shearn C.T., Smathers R.L., Backos D.S., Reigan P., Orlicky D.J., Petersen D.R. Increased carbonylation of the lipid phosphatase PTEN contributes to Akt2 activation in a murine model of early alcohol-induced steatosis. Free Radic. Biol. Med. 2013, 65:680-692.
35. Duan X.Y., Zhao H.P., Fan J.G. Dynamic expression of hepatic thioredoxin mRNA in rats with non-alcoholic fatty liver disease. J. Digest. Dis. 2010, 11:94-100.
36. Okuyama H., Nakamura H., Shimahara Y., Uyama N., Kwon Y.W., Kawada N., et al. Overexpression of thioredoxin prevents thioacetamide-induced hepatic fibrosis in mice. J. Hepatol. 2005, 42:117-123.
37. Bell L.N., Theodorakis J.L., Vuppalanchi R., Saxena R., Bemis K.G., Wang M., et al. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010, 51:111-120.
38. Fujii T., Fuchs B.C., Yamada S., Lauwers G.Y., Kulu Y., Goodwin J.M., et al. Mouse model of carbon tetrachloride-induced liver fibrosis: histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol. 2010, 10:79.
39. Fiorucci S., Antonelli E., Distrutti E., Severino B., Fiorentina R., Baldoni M., et al. PAR1 antagonism protects against experimental liver fibrosis: role of proteinase receptors in stellate cell activation. Hepatology 2004, 39:365-375.
40. Anstee Q.M., Goldin R.D., Wright M., Martinelli A., Martinelli A., Cox R., et al. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J. Thromb. Haemostasis 2008, 6:1336-1343.
41. Tian L., Wang Y., Xu D., Gao Y., Wen X., Tian Y. The differential diagnostic model for serous peptidomics in HBV carriers established by MALDI-TOF-MS analysis. Clin. Biochem. 2014, 47:56-62.
42. Green G., Poller L., Thomson J.M., Dymock I.W. Factor VII as a marker of hepatocellular synthetic function in liver disease. J. Clin. Pathol. 1976, 29:971-975.
43. Saja M.F., Abdo A.A., Sanai F.M., Shaikh S.A., Gader A.G. The coagulopathy of liver disease: does vitamin K help?. Blood Coagul. Fibrin. 2013, 24:10-17.